Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Sold 1% of the company…..still holds 7%. This is most likely Just profit taking and portfolio management.
Octopus has a successful IHT investment portfolio based on AIM assets…it has a need to diversify across AIM.
An encouraging update…..vets have pricing power and customer loyalty and will be alright in an inflationary environment.
They will suffer if there is a reduction in pet ownership and farming of animals as meat alternatives are promoted as a climate friendly alternative.
Should beat the market today but whether that is up or down we will have to see..
CVS moves from strength to strength. EBITDA expectedbto be marginally ahead of April's upgraded market expectations. This should bounce back today and hopefully will encourage analysts this still has further to go. Leverage down, employment up. Board are continually under promising and over delivering. cant be a bad thing for us. Let's hope the market responds well amidst general inflation concerns.
Trading update on Tuesday per telegraph
Last year there was a trading update on 24 July and full results 24 Sept.
No reason to expect anything different this year.
Apr update was positive…..valuation is high in expectation of growth….hopefully the results are excellent to bring the P/E ratio down quite a lot.
Not expecting much in the way of gains as already fully valued.
The now regular pre results rush to buy shares has started. There must be some investors being informed of the positive news that is imminent. Enjoy the ride!
CVS and pets share prices have never moved in tandum, so puzzled by positive predictions relating to pets at home.
Eye wateringly incredible results from PETS this morning. This shows what CVS are currently sitting on. Very excited for full year CVS results.
The market is warming back up ahead of Pets at Home results being reported on Thursday. Sales within the vet sector are flying so these results will be first indicator of how strong CVS results will be come June. Looks like some people in the know are adding CVS shares currently. Still a lot to like here.
Momentum seems to moving the SP to a point where market cap seems unjustified. Currently 1.3bn! Just need revenue up so PEG doesn’t run away with self...currently trading at 2-3 ratio PEG with an expected 30-40% revenue increase.
The dilemma I’m faced with is Hold tight or scale back a bit?
And two broker upgrades to 2400 and 2750. (See news section)
Still some room to grow in this market.
Think we can expect another good trading update in July.
Well here's a nice surprise. Unusual to get a trading update at this point in the year but just a brief one to say sales have increased over the very positive last quarter. Therefore again, sales have grown above the previous level that was already above expectations. Unusual for CVS Board to be so positive so a LOT to like here. Interesting to see what the market makes of this seemingly under the radar stock.
The veterinary sector really is on fire at the moment. This share has some ground to catch up and from recent figures and given other activity in this region a £24-25 price seems reasonable. I'm firmly holding and will add if goes sub 19.
SP now seems rather over the top. Do not see £20 and over being achieved for very long.
Currently sitting at a market cap of 1.4bn. This feels a bit too heavy. Earnings need to be very good in the coming year to support this. PE is racing away.
ROCE needs to move back to average of around +20% and Margins need to move back to around +40%. But both are capable and within reach for the business. Got a solid holding but will top up more if these come through. Newish CEO, CFO, and COO so another factor to consider in terms vested interest and support.
They are actively addressing the lack of Vet specialist problem which is positive.
On watch with excitement.
And this..
https://www.ft.com/content/9a825fe8-8ea5-4ef3-84b7-2529bfe5ffed
Still a lot to like in this share.
Lots of big money news in this sector in last 24 hours. MEDIVET is a smaller corporate in the sector that is up for auction:
https://news.sky.com/story/medivet-to-cash-in-on-pandemic-pets-boom-with-1bn-sale-12282470
Sky reporting that Medivet will be auctioned by its PE owner.
300 practices, for 1bn.
If it is out of CVSGs league it is a useful benchmark for enterprise value.
Some interesting facts,
Controls 20% of uk market within a European business. UK market up 57% sales in 5 years.
leased assets and debt are six times EBITDA (2 values of £248m and 322m (eur?) used)
Latest valuation about £10bn.
Article generally critical of PE and practices ramping up Drug costs.
Having just taken my cat to the v e t they sure know how to charge.
And that was a good week. There's certainly more to come.
Been a good year though on this one. Can’t complain.
This dip has proved a rdip in SPleal buying opportunity. NE Director buying, Investors Chronicle reiterating buy advice and Daily Telegraph moving to sell (grudgingly) citing the fact that this share burnt their fingers in 2017. Will reach £20 again and surpass it. CEO even said in update ot is better to under promise and as good as stating the current months are record breaking and well above broker expectations. I've bought more!
Someone is listening....Peel Hunt ups target to 21
Indeed, EPS for the half year is around the best result for annual profits in 2017/18 when it was 18 then 16p.
Great fall in debt which appeared to be the downfall of the share when it traded much lower after several profit warnings.
Back to being a growth company.
Year on year figures show EBITDA up 38%, EPS up 100%, operating profit up 55%, staff vacancy rate stable net debt is down over 50%.
Not a bad figure in there. My guesstimate of £20 seems undervalued.
Somebody please nudge the analysts, current ratings arent close to matching recent trading updates.
Buy buy buy buy buy buy buy!